Ionis to host 2022 virtual Annual Meeting of Stockholders
CARLSBAD, Calif., May 2, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022.
The agenda for the event is as follows:
- 5:00 p.m. ? 5:15 p.m. ET (2:00 p.m. ? 2:15 p.m. PT) ? Virtual Annual Meeting of Stockholders
All stockholders of record at the close of business on April 5, 2022 are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at http://www.virtualshareholdermeeting.com/IONS2022.
Stockholders of record will receive an official proxy card, which contains important information, including a 16-digit control number, required to log-in, vote and submit questions during the Annual Meeting webcast.
Proxy cards are mailed to stockholders from their brokerage firm. Ionis does not provide proxy cards or have access to proxy card information, including 16-digit control numbers.
Stockholders should contact their brokerage firm at least 5 days in advance of the meeting for help obtaining a proxy card or to locate their control number or for instructions to access the Webcast.
A help line will be available on the registration page for the live Annual Meeting webcast for participants requiring technical assistance in accessing or participating in the live event. There will not be a replay of the live Annual Meeting.
- 5:30 p.m. ? 6:30 p.m. ET (2:30 p.m. ? 3:30 p.m. PT) ? Virtual corporate update presented by Brett P. Monia, Ph.D., Ionis' chief executive officer
About Ionis Pharmaceuticals For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
The "Consumer Brain-Computer Interface: Market and Product Development Trends" report has been added to ResearchAndMarkets.com's offering.
Over the past decade, brain-computer interface (BCI) technology has expanded beyond the confines of the...
Caravelle International Group , a global ocean technology company, today announced that it received a notice from The Nasdaq Stock Market LLC indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the fiscal year...
On 29 March 2024, BTR New Material Group Co., Ltd. ("BTR")(835185.BJ), a global leader in battery materials, inked an investment agreement with the Moroccan government to erect a lithium battery ternary cathode material facility in the country. The...
Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie)?announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow...
AERKOMM Inc. (Euronext: AKOM, OTCQX: AKOM, "AERKOMM"), an innovative satellite technology company providing multi-orbit broadband connectivity solutions, and IX Acquisition Corp , a SPAC focused on the technology, media and telecommunications...
SparkFun Electronics introduces the SparkFun Pulsed Coherent Radar Sensor ? Acconeer XM125 (Qwiic), opening up a world of possibilities for those looking to easily utilize a complex and powerful technology. This cutting-edge sensor brings 60 GHz...